CorVel (NASDAQ:CRVL – Get Free Report) released its quarterly earnings data on Tuesday. The business services provider reported $0.61 earnings per share for the quarter, FiscalAI reports. CorVel had a return on equity of 30.15% and a net margin of 11.23%.The business had revenue of $248.55 million during the quarter.
CorVel Stock Performance
NASDAQ CRVL opened at $58.82 on Wednesday. The company has a market capitalization of $3.01 billion, a PE ratio of 28.83 and a beta of 0.98. The business’s fifty day moving average is $55.29 and its 200 day moving average is $61.89. CorVel has a fifty-two week low of $44.83 and a fifty-two week high of $117.22.
Insider Activity at CorVel
In other news, insider Maxim Shishin sold 2,400 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $54.00, for a total value of $129,600.00. Following the transaction, the insider directly owned 7,050 shares in the company, valued at $380,700. The trade was a 25.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 44.56% of the stock is owned by insiders.
Institutional Investors Weigh In On CorVel
Analyst Ratings Changes
Separately, Weiss Ratings cut CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, April 6th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.
Check Out Our Latest Report on CRVL
About CorVel
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
Featured Articles
- Five stocks we like better than CorVel
- Vertical Aerospace: Pre-Flight Checks Point to a Breakout
- Palo Alto Networks Up 70%: Can the Rally Last Into June?
- Block’s Pivot to Profits and AI Is Turning Heads
- HIVE Weaponizes Power for an AI Pivot
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.
